One main goal of anti-cancer therapies is to kill tumor cells without affecting the surrounding normal cells. Therefore, many ...

A team of scientists from The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has identified ...

The first patient with relapsed or refractory acute myeloid leukemia has been dosed with Annamycin plus Cytarabine in the ...

A team of scientists from The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has identified a promising new drug target for acute myeloid leukemia (AML), a deadly ...

Scientists have identified a promising new drug target for acute myeloid leukemia, a deadly blood cancer with a five-year ...

Breakthroughs in combination drug-therapies, including BCL2 protein inhibitors and FLT3 gene inhibitors, are offering dramatically improved responses. Since 2012, when acute myeloid leukemia (AML) ...

The start of patient dosing represents a huge milestone for Moleculin and, importantly, the AML community. “Our team rem ...